- Home
- COCO vs ARQT Comparison
COCO vs ARQT Comparison
Compare COCO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCO
- ARQT
- Stock Information
- Founded
- COCO 2004
- ARQT 2016
- Country
- COCO United States
- ARQT United States
- Employees
- COCO N/A
- ARQT N/A
- Industry
- COCO Beverages (Production/Distribution)
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- COCO Consumer Staples
- ARQT Health Care
- Exchange
- COCO Nasdaq
- ARQT Nasdaq
- Market Cap
- COCO N/A
- ARQT 2.0B
- IPO Year
- COCO 2021
- ARQT 2020
- Fundamental
- Price
- COCO $30.15
- ARQT $14.98
- Analyst Decision
- COCO Buy
- ARQT Strong Buy
- Analyst Count
- COCO 6
- ARQT 6
- Target Price
- COCO $35.17
- ARQT $18.80
- AVG Volume (30 Days)
- COCO 705.6K
- ARQT 2.5M
- Earning Date
- COCO 04-30-2025
- ARQT 05-13-2025
- Dividend Yield
- COCO N/A
- ARQT N/A
- EPS Growth
- COCO 18.99
- ARQT N/A
- EPS
- COCO 0.94
- ARQT N/A
- Revenue
- COCO $516,013,000.00
- ARQT $196,542,000.00
- Revenue This Year
- COCO $12.42
- ARQT $56.60
- Revenue Next Year
- COCO $10.73
- ARQT $43.62
- P/E Ratio
- COCO $31.94
- ARQT N/A
- Revenue Growth
- COCO 4.54
- ARQT 229.74
- 52 Week Low
- COCO $23.00
- ARQT $6.99
- 52 Week High
- COCO $40.32
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- COCO 35.85
- ARQT 48.01
- Support Level
- COCO $29.39
- ARQT $14.76
- Resistance Level
- COCO $31.20
- ARQT $17.75
- Average True Range (ATR)
- COCO 1.30
- ARQT 1.09
- MACD
- COCO -0.42
- ARQT -0.18
- Stochastic Oscillator
- COCO 21.03
- ARQT 20.63
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.